Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Abraxis BioScience to Present at the Merriman Curhan Ford Investor Summit and Lazard Capital Markets Healthcare Conference

Abstract:
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, announced today that management will present a company overview.

Abraxis BioScience to Present at the Merriman Curhan Ford Investor Summit and Lazard Capital Markets Healthcare Conference

Posted on October 16th, 2009

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, announced today that management will present a company overview at the following two upcoming conferences:

Merriman Curhan Ford 6th Annual Investor Summit

Date: Tuesday, November 10, 2009
Time: 10:00 a.m. EST
Location: Hotel Sofitel New York

Lazard Capital Markets 6th Annual Healthcare Conference

Date: Tuesday, November 17, 2009
Time: 9:25 a.m. EST
Location: The St. Regis hotel in New York

A live webcast of each presentation will be available in the Investor Relations section of the company's website at www.abraxisbio.com. The webcasts will be archived and accessible for at least 30 days.

####

About Abraxis BioScience
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE®), which is based on the company's proprietary tumor targeting technology known as the nab® platform. The first FDA approved product to use this nab platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 38 countries. The company continues to expand the nab platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII.

For more information, please click here

Contacts:
Investor & Media Inquiries
Abraxis BioScience, Inc.
Maili Bergman
Director Investor Relations & Corporate Communications
310-883-1300

or
PondelWilkinson Inc.
Rob Whetstone, 310-279-5963

Copyright © Abraxis BioScience

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease February 22nd, 2018

MEMS chips get metatlenses: Combining metasurface lenses with MEMS technology could add high-speed scanning and enhance focusing capability of optical systems February 21st, 2018

Atomic structure of ultrasound material not what anyone expected February 21st, 2018

Oxford Instruments announces Dr Kate Ross as winner of the 2018 Lee Osheroff Richardson Science Prize for North and South America February 20th, 2018

Announcements

Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease February 22nd, 2018

MEMS chips get metatlenses: Combining metasurface lenses with MEMS technology could add high-speed scanning and enhance focusing capability of optical systems February 21st, 2018

Atomic structure of ultrasound material not what anyone expected February 21st, 2018

Oxford Instruments announces Dr Kate Ross as winner of the 2018 Lee Osheroff Richardson Science Prize for North and South America February 20th, 2018

Events/Classes

European & Korean Project To Demo World’s First 5G Platform During Winter Games February 15th, 2018

Leti’s Chief Scientist Presents Optimistic Vision for Neuromorphic Hardware and Ultra-Low-Power Microdevices for Edge Computing at ISSCC: Leti’s Chief Scientist Presents Optimistic Vision for Neuromorphic Hardware and Ultra-Low-Power Microdevices That Are Based on Novel Emerging February 13th, 2018

Leti Chief Scientist Barbara De Salvo Will Help Kick Off ISSCC 2018 with Opening-Day Keynote: In Addition, Leti Scientists Will Present and Demo New Technology for Piezoelectric Energy Harvesting February 8th, 2018

Leti Presents Optical-Equipment Curving Technology that Improves Performance, Cuts Costs: ‘Disruptive Approach’ for Imaging Applications Presented in Paper At Photonics West and Demonstrated in Leti’s Booth February 2nd, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project